BioXcel Therapeutics (BTAI) Treasury Shares (2022 - 2026)

BioXcel Therapeutics' Treasury Shares history runs 5 years deep, the most recent figure standing at $512000.0 for Q1 2026.

• On a quarterly basis, Treasury Shares rose 47219.78% year-over-year to $512000.0 in Q1 2026; TTM through Mar 2026 was $512000.0, a 47219.78% increase from a year earlier, with the FY2025 full-year figure at $107000.0, down 90.82% from the prior year.
• Treasury Shares climbed to $512000.0 in Q1 2026 per BTAI's latest filing, from $107000.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $1.2 million in Q4 2024 and bottomed at $137.0 in Q3 2025.
• The 5-year median for Treasury Shares is $34500.0 (2023), against an average of $175281.1.
• Across the five-year window, Treasury Shares sank 99.79% in 2025 and soared 47219.78% in 2026, its largest moves.
• Year by year, Treasury Shares stood at $1310.0 in 2022, then jumped by 816.03% to $12000.0 in 2023, then jumped by 9616.67% to $1.2 million in 2024, then sank by 90.82% to $107000.0 in 2025, then soared by 378.5% to $512000.0 in 2026.
• Per Business Quant, the three latest BTAI Treasury Shares figures stand at $512000.0 (Q1 2026), $107000.0 (Q4 2025), and $137.0 (Q3 2025).